In vivo AD mouse models that were treated with GW4869, an inhibitor of nSMase2 which thusly prevents EV secretion, showed reduced levels of Aβ42, and a reduction in the number of amyloid plaques in the brain, suggesting that EV secretion plays a significant role in the accumulation and aggregation of Aβ42 in AD pathology (Dinkins et al., 2014). The gene discussed is SMPD3; the disease is Alzheimer disease.